Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCYY5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $95,242
Award facts
- Contract value 100% obligated
- $95,242.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $95,242.06 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, represents a routine pharmaceutical delivery under the agency's medical supply operations. DMS Pharmaceutical Group was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order falls under the company's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion government-wide acquisition strategy designed to support recurring pharmaceutical supply needs for Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's selection reflects its established position as a critical pharmaceutical supplier within the federal military medical system. The company maintains a comprehensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with demonstrated performance across numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. The PPV-G GEN V contract, awarded on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting DoD healthcare operations globally through a 30-month base period with three 30-month option periods.
Quick answers
Who was awarded contract SPE2DR26FCYY5?
SPE2DR26FCYY5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FCYY5 worth?
The government has obligated $95,242 on SPE2DR26FCYY5.
Is contract SPE2DR26FCYY5 an order under another contract?
Yes. SPE2DR26FCYY5 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCYY5 competed?
The extent of competition for SPE2DR26FCYY5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award